Thrivent Financial for Lutherans Sells 17,146 Shares of LivaNova PLC (NASDAQ:LIVN)

Thrivent Financial for Lutherans cut its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 57.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,757 shares of the company’s stock after selling 17,146 shares during the period. Thrivent Financial for Lutherans’ holdings in LivaNova were worth $670,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the business. Price T Rowe Associates Inc. MD boosted its position in LivaNova by 6.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 31,021 shares of the company’s stock valued at $1,736,000 after buying an additional 1,980 shares during the last quarter. Hexagon Capital Partners LLC boosted its position in LivaNova by 117.8% in the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock valued at $37,000 after buying an additional 370 shares during the last quarter. Diversified Trust Co boosted its position in LivaNova by 7.9% in the 2nd quarter. Diversified Trust Co now owns 13,902 shares of the company’s stock valued at $762,000 after buying an additional 1,012 shares during the last quarter. Fifth Third Bancorp boosted its position in LivaNova by 97.1% in the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock valued at $37,000 after buying an additional 332 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in LivaNova by 4.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 506,105 shares of the company’s stock valued at $27,745,000 after buying an additional 20,275 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have commented on LIVN shares. Robert W. Baird increased their price objective on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. StockNews.com lowered LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 16th. The Goldman Sachs Group began coverage on LivaNova in a research report on Friday, October 4th. They issued a “buy” rating and a $65.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and issued a $75.00 price target on shares of LivaNova in a research report on Monday, November 25th. Finally, Mizuho reduced their price target on LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $69.17.

LivaNova Stock Down 0.8 %

NASDAQ:LIVN opened at $51.19 on Thursday. LivaNova PLC has a 12-month low of $42.75 and a 12-month high of $64.47. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $2.78 billion, a P/E ratio of 121.88 and a beta of 0.98. The stock’s fifty day simple moving average is $52.28 and its 200-day simple moving average is $51.95.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.